Clinical Interventions in Aging

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis

Hisaya Kawate
Ryoichi Takayanagi
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Abstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues. Two large Phase III clinical trials showed that bazedoxifene, as well as raloxifene, increased bone mineral density, decreased levels of bone turnover markers, and significantly reduced the risk of new vertebral fractures in postmenopausal women compared with placebo. Although the incidence of nonvertebral fractures with bazedoxifene or raloxifene did not differ significantly from that with placebo, a post hoc analysis of a subgroup of women at higher fracture risk revealed that bazedoxifene significantly reduced the nonvertebral fracture risk relative to placebo and raloxifene. Bazedoxifene also improved the lipid profile by reducing the serum concentrations of total cholesterol and low-density lipoprotein cholesterol, with an increase in the serum level of high-density lipoprotein cholesterol. The incidences of vasodilatation (hot flushes), leg cramps, and venous thromboembolic events were significantly higher with bazedoxifene and raloxifene compared with placebo. There was no evidence of endometrial and breast stimulation with bazedoxifene. Taking advantage of the favorable effects of bazedoxifene on the breast and endometrium, the pairing of bazedoxifene with conjugated estrogens is under investigation for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. A Phase III trial showed that combination therapy of bazedoxifene and conjugated estrogens significantly increased bone mineral density and decreased bone turnover markers, with relief of hot flushes and improvement of vaginal atrophy. This article reviews the clinical efficacy and safety of bazedoxifene in the treatment of postmenopausal osteoporosis.

Keywords: selective estrogen receptor modulators, osteoporosis, estrogen receptor, nonvertebral fracture, endometrium

Introduction

Osteoporosis is a systemic skeletal disease characterized by loss of bone mass and strength, which leads to bone fragility and increased susceptibility to fractures.\textsuperscript{1,2} Osteoporotic fractures, which usually occur at the spine, hip, and distal radius, impact negatively on quality of life and increase both morbidity and mortality.\textsuperscript{3-6} Health care costs for patients with osteoporotic fractures are anticipated to rise in parallel with the increase in elderly populations. Treatment of osteoporotic patients is important for both preventing osteoporotic fractures and reducing the associated health care burden.

Declining levels of endogenous estrogens mainly contribute to rapid bone loss at the time of menopause, leading to postmenopausal osteoporosis. It has been demonstrated that long-term hormone replacement therapy with estrogen plus progestin prevents bone loss and fractures.\textsuperscript{7,8} However, large randomized controlled trials had
suggested that hormone replacement therapy increased the risk of breast cancer, although they have demonstrated that hormone replacement therapy significantly reduced the risk of osteoporotic fractures. To avoid such negative aspects of estrogen action, selective estrogen receptor modulators (SERMs), which act as estrogen receptor agonists in some tissues and as estrogen receptor antagonists in others, have been developed (Figure 1). An ideal SERM would have beneficial agonistic effects on bone, the cardiovascular system, and the central nervous system to prevent bone loss and cardiovascular events, but have anti-estrogenic effects on the breast and endometrium to reduce the risk of breast and endometrial cancers.

Tamoxifen was the first SERM used clinically to reduce the risk of breast cancer in high-risk women. It was also reported that tamoxifen maintained bone mineral density in postmenopausal women. However, long-term treatment with tamoxifen increased the risks of endometrial cancer and blood clots, related to the partial estrogen receptor agonistic activity of this compound. Raloxifene was also found to be an effective estrogen receptor antagonist against breast cancer. In addition to its lack of proliferative effects on the uterus, unlike tamoxifen, raloxifene was shown to decrease plasma cholesterol levels and prevent decreases in bone mineral density. Raloxifene acts as an estrogen agonist in bone and lipid metabolism but an estrogen antagonist in the breast. Raloxifene is the first SERM to have been approved by the US Food and Drug Administration for the prevention and treatment of postmenopausal osteoporosis.

Bazedoxifene is a third-generation SERM, which was recently approved for the treatment of postmenopausal osteoporosis in Europe and Japan. This comprehensive review describes the efficacy and safety of bazedoxifene in patients with osteoporosis.

**Bazedoxifene**

Bazedoxifene acetate (WAY-140424, TSE-424) is an indole-based estrogen receptor ligand with unique structural characteristics (Figure 1). The molecule was assembled by using raloxifene as a template and substituting an indole ring for the benzothioprine core. To select this novel SERM, a stringent selection process was implemented to assess its biological activity and tissue selectivity on key endpoints, which included the uterus, lipid metabolism, bone remodeling, and central nervous system function.

**Preclinical research**

**In vitro studies**

Bazedoxifene binds to both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with IC₅₀ values of 23 ± 15 nM.
and 85 ± 59 nM, respectively, and a slight preference for ERα.19,21 Its affinity for ERα is about 10-fold lower than that of 17β-estradiol (IC₅₀ 3 ± 1 nM) and raloxifene (IC₅₀ 4 ± 3 nM). Bazedoxifene competitively inhibits 17β-estradiol binding to both ERα (dissociation constant for bazedoxifene 0.1 nM) and ERβ (0.3 nM). In MCF-7 breast cancer cells, bazedoxifene showed no estrogen receptor agonist activity, but inhibited 17β-estradiol-induced transcriptional activation.19,21 Bazedoxifene did not stimulate the proliferation of MCF-7 cells, but did inhibit 17β-estradiol-induced proliferation in a dose-dependent manner.19,21

**Effects on bone**
In a 6-week ovariectomized rat model, bazedoxifene 0.3 mg/kg/day consistently and significantly increased bone mass compared with control animals.19,21 The vertebral compressive strength in bazedoxifene-treated ovariectomized rats was equivalent to or better than that in sham-operated animals and significantly better than that in vehicle-treated ovariectomized animals.21 Bone histology was also maintained in bazedoxifene-treated ovariectomized rats.

**Endometrial effects**
In an immature rat uterine model, ethinyl estradiol increased the wet uterine weight after 3 days of treatment. Bazedoxifene 0.5 mg/kg and 5.0 mg/kg was associated with a smaller increase in wet uterine weight than either ethinyl estradiol or raloxifene.21 Histological examination revealed that bazedoxifene did not cause luminal epithelial cell hyperplasia or hyperplasia, myometrial hypertrophy, or luminal distention. Cotreatment of bazedoxifene and raloxifene completely abrogated stimulation of luminal epithelial cells and the myometrium by raloxifene, supporting an improved uterine profile for bazedoxifene.21 Anti-estrogenic effects of bazedoxifene on the endometrium were also confirmed in an ovariectomized mouse model.22

**Vasomotor effects**
In a morphine-addicted rat model of vasomotor activity, naloxone injection resulted in a rapid rise in tail skin temperature. The increase in tail skin temperature was abrogated in rats pretreated with estrogen receptor agonists. Similar to raloxifene, bazedoxifene did not act as an estrogen receptor agonist in this model. When a bone-sparing dose (0.3 mg/kg/day) of bazedoxifene was coadministered with ethinyl estradiol, no antagonism was detected, which may indicate a potential lack of a vasomotor effect of bazedoxifene in postmenopausal women.21

**Mammary glands**
In a study comparing the relative effects of SERMs on the mammary gland of ovariectomized mice, bazedoxifene exhibited less agonist activity and was a more effective antagonist of conjugated estrogens in the mammary gland than other SERMs, ie, raloxifene and lasofoxifene, as assessed by both gene expression and morphology of the mammary gland.22

**Lipid profiles**
In a 6-week ovariectomized rat study, bazedoxifene significantly reduced total cholesterol level as effectively as raloxifene.19,21

**Clinical studies**

**Clinical pharmacokinetics and metabolism**
In a Phase I dose-proportionality study in healthy postmenopausal women, bazedoxifene reached a maximum plasma concentration at 1–2 hours after oral administration, and its half-life was approximately 28 hours. A steady-state plasma concentration was achieved by day 7, and linear pharmacokinetics were observed in the dose range tested (5–40 mg).21 The metabolic profile of bazedoxifene was analyzed using a single oral dose of [14C]bazedoxifene 20 mg. The major route of excretion was the feces (84.7%), with less than 1% excreted in the urine. The predominant metabolite was bazedoxifene-5-glucuronide (40%–95%).24 There was little or no cytochrome P450-mediated metabolism of bazedoxifene.

**Phase II clinical efficacy and safety**
A 3-month, randomized, placebo-controlled study demonstrated that bazedoxifene reduced bone turnover markers in healthy postmenopausal women (n = 494) in a dose-dependent manner.25 A 6-month, double-blind, randomized study of healthy postmenopausal women (n = 497) assessed the endometrial effects of bazedoxifene.26 No significant differences in endometrial thickness were observed from baseline for bazedoxifene doses of 2.5–20 mg/day. On the other hand, significant decreases in endometrial thickness and decreased uterine bleeding were observed for bazedoxifene doses of 30 mg and 40 mg compared with placebo.26 The incidence of breast pain was also significantly lower in the bazedoxifene 40 mg group than in the placebo group.27

**Phase III clinical trials**
Two large, prospective, global Phase III trials of bazedoxifene for osteoporosis prevention and treatment have been...
completed. Both studies were randomized, double-blind trials and included a placebo and a positive control (raloxifene).

Two-year Phase III study
In a 2-year Phase III study, a total of 1583 healthy postmenopausal women with a bone mineral density T score at the lumbar spine or femoral neck between −1.0 and −2.5 or clinical risk factors for osteoporosis were randomly assigned to one of five groups, ie, bazedoxifene 10, 20, or 40 mg/day, placebo, or raloxifene 60 mg/day. All the women received daily supplementation with elemental calcium 600 mg. Compared with placebo, all doses of bazedoxifene and raloxifene prevented bone loss at all skeletal sites. The mean differences in percent change in lumbar spine bone density from baseline to 24 months relative to placebo were 1.08% ± 0.28%, 1.41% ± 0.28%, and 1.49% ± 0.28% for bazedoxifene 10, 20, and 40 mg, respectively ($P < 0.001$ for all comparisons). All the bazedoxifene treatment groups had significantly greater bone mineral density at the total hip in comparison with the placebo group at 6, 12, 18, and 24 months. Significant reductions in serum levels of osteocalcin and cross-linked C-terminal telopeptide of type I collagen from baseline and relative to placebo were observed for all doses of bazedoxifene and raloxifene treatment as early as 3 months, and were sustained until the end of the study ($P < 0.001$). Serum concentrations of total cholesterol and low-density lipoprotein cholesterol were decreased with bazedoxifene and raloxifene treatment compared with placebo, whereas serum levels of high-density lipoprotein cholesterol were elevated after treatment with the SERMs. Although significant increases from baseline in the median concentrations of triglycerides were observed among women receiving bazedoxifene 20 mg and 40 mg and placebo, there were no significant differences between the groups. The overall incidences of adverse events, serious adverse events, and discontinuations caused by adverse events were similar among the groups (Table 1). The most common adverse events included headache, infection, arthralgia, pain, hot flushes, and back pain.

Three-year Phase III study
In a 3-year Phase III study, 7492 healthy postmenopausal women aged 55–85 years with osteoporosis, defined by low bone mineral density or radiographically confirmed vertebral fractures, were randomized to treatment with bazedoxifene 20 or 40 mg/day, raloxifene 60 mg/day, or placebo. All the subjects received daily oral calcium ≥1200 mg and vitamin D 400–800 IU supplementation. The primary endpoint was the incidence of new vertebral fractures after 36 months and secondary endpoints included nonvertebral fractures, bone mineral density, and bone turnover markers. Treatment with bazedoxifene 20 and 40 mg and raloxifene 60 mg significantly increased lumbar spine and total hip bone mineral density (Figure 2) and reduced serum levels of osteocalcin and C-terminal telopeptide of type I collagen compared with placebo. Among 6847 subjects in the intention-to-treat population, the incidence of new vertebral fractures was significantly lower ($P < 0.05$) for bazedoxifene 20 mg (2.3%), bazedoxifene 40 mg (2.5%), and raloxifene 60 mg (2.3%) compared with placebo (4.1%). Relative to

Table 1 Safety profile of bazedoxifene in two Phase III trials

<table>
<thead>
<tr>
<th>Adverse event, n (%)</th>
<th>2-year study&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Raloxifene (n = 311)</th>
<th>Placebo (n = 310)</th>
<th>3-year study&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Raloxifene (n = 1849)</th>
<th>Placebo (n = 1885)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adverse event</td>
<td>916 (95.2)</td>
<td>309 (96.0)</td>
<td>297 (95.8)</td>
<td>3598 (95.7)</td>
<td>1775 (96.0)</td>
<td>1813 (96.2)</td>
</tr>
<tr>
<td>Any serious adverse event</td>
<td>99 (10.3)</td>
<td>29 (9.3)</td>
<td>28 (9.0)</td>
<td>750 (20.0)</td>
<td>344 (18.6)</td>
<td>353 (18.7)</td>
</tr>
<tr>
<td>Discontinuations caused by AE</td>
<td>167 (17.4)</td>
<td>43 (13.8)</td>
<td>48 (15.5)</td>
<td>539 (14.3)</td>
<td>262 (14.2)</td>
<td>240 (12.7)</td>
</tr>
<tr>
<td><strong>Selected adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>3 (0.3)</td>
<td>0</td>
<td>1 (0.3)</td>
<td>16 (0.4)</td>
<td>6 (0.3)</td>
<td>8 (0.4)</td>
</tr>
<tr>
<td>Strokes</td>
<td>2 (0.2)</td>
<td>1 (0.3)</td>
<td>0</td>
<td>38 (1.0)</td>
<td>15 (0.8)</td>
<td>20 (1.1)</td>
</tr>
<tr>
<td>Deep vein thrombosis</td>
<td>2 (0.2)</td>
<td>0</td>
<td>1 (0.3)</td>
<td>18 (0.5)</td>
<td>8 (0.4)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Pulmonary embolus</td>
<td>1 (0.1)</td>
<td>0</td>
<td>0</td>
<td>8 (0.2)</td>
<td>4 (0.2)</td>
<td>4 (0.2)</td>
</tr>
<tr>
<td>Retinal vein thrombosis</td>
<td>0</td>
<td>1 (0.3)</td>
<td>0</td>
<td>3 (0.1)</td>
<td>0</td>
<td>3 (0.2)</td>
</tr>
<tr>
<td>Hot flushes</td>
<td>207 (21.5)</td>
<td>58 (18.6)</td>
<td>44 (14.2)</td>
<td>481 (12.8)</td>
<td>222 (12.0)</td>
<td>118 (6.3)</td>
</tr>
<tr>
<td>Leg cramps</td>
<td>107 (11.1)</td>
<td>37 (11.9)</td>
<td>36 (11.6)</td>
<td>409 (10.9)</td>
<td>216 (11.7)</td>
<td>155 (8.2)</td>
</tr>
<tr>
<td>Endometrial carcinoma</td>
<td>0</td>
<td>1 (0.3)</td>
<td>0</td>
<td>2 (0.05)</td>
<td>2 (0.1)</td>
<td>3 (0.2)</td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (0.05)</td>
<td>1 (0.1)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Breast carcinoma</td>
<td>3 (0.3)</td>
<td>1 (0.3)</td>
<td>2 (0.6)</td>
<td>9 (0.2)</td>
<td>7 (0.4)</td>
<td>8 (0.4)</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>Total number of subjects who received bazedoxifene 10, 20, or 40 mg/day; <sup>b</sup>Total number of subjects who received bazedoxifene 20 or 40 mg/day.

Abbreviation: AE, adverse event.
placebo, bazedoxifene 20 mg and 40 mg and raloxifene 60 mg reduced the risk of new vertebral fractures by 42%, 37%, and 42%, respectively (Figure 3). There were no significant differences in the incidence of new vertebral fractures between the bazedoxifene and raloxifene treatment groups. The incidence of nonvertebral fractures with bazedoxifene 20 mg (5.7%) and 40 mg (5.6%) and raloxifene 60 mg (5.9%) did not differ significantly from placebo (6.3%, Figure 3). However, in a post hoc analysis of a subgroup of women at higher fracture risk (femoral neck T score \( \leq -3.0 \) and/or at least one moderate or severe vertebral fracture or multiple mild vertebral fractures; \( n = 1772 \)), bazedoxifene...
20 mg showed 50% and 44% reductions in nonvertebral fracture risk relative to placebo ($P = 0.02$) and raloxifene 60 mg ($P = 0.05$), respectively (Figure 4). A similar reduction in nonvertebral fracture incidence was observed with bazedoxifene 40 mg, but the difference was not statistically significant (Figure 4).

An independent re-evaluation of fracture data from the Phase III study was performed using the Fracture Risk Assessment Tool (FRAX®) algorithm developed by the World Health Organization to estimate 10-year fracture risk. In patients with a 10-year fracture risk of 6.9%, bazedoxifene was associated with a significant decrease in risk of morphometric vertebral fractures. Moreover, in patients with 10-year fracture probabilities at or above 16%, bazedoxifene was associated with a significant decrease in risk of all clinical fractures.

In the 3-year Phase III trial, bazedoxifene 20 mg and 40 mg doses were well tolerated. The incidences of adverse events, serious adverse events, discontinuations because of adverse events, and deaths in the bazedoxifene groups were generally similar to those in the placebo group (Table 1).

The most common adverse events were abdominal pain, accidental injury, arthralgia, back pain, flu syndrome, headache, hypertension, infection, and pain. The incidences of vasodilatation (hot flushes) and leg cramps were similar among the bazedoxifene and raloxifene treatment groups and significantly higher than those in the placebo group (Table 1). Most cases of vasodilatation were mild to moderate in severity and did not lead to discontinuation of therapy. The overall frequencies of cardiovascular events and stroke were low, and evenly distributed among the groups. The incidence of venous thromboembolic events (deep vein thrombosis and/or pulmonary embolism) was higher in the active treatment groups than in the placebo group, primarily because of an increased incidence of deep vein thrombosis, although the overall incidence of venous thromboembolic events in the active treatment groups was very low ($<1\%$, Table 1). There was no significant difference in the incidence of venous thromboembolic events among the bazedoxifene and raloxifene treatment groups.

### Breast and endometrial safety

Breast and endometrial safety is an important issue in the clinical development of new SERMs. Special attention was...
In the 2-year Phase III trial, bazedoxifene was not associated with a significant change from baseline in mean endometrial thickness compared with placebo. There was no consensus diagnosis of endometrial hyperplasia or malignancy in the bazedoxifene and raloxifene groups (Table 1). There were no significant differences among the groups in the change from baseline in ovarian volume, number or size of ovarian cysts, or incidence of ovarian cancer. Reports of breast pain and breast cancer were low, and evenly distributed among the groups.28,33

In the 3-year Phase III trial, there were no significant changes in the mean endometrial thickness from baseline or in the incidence of endometrial hyperplasia and endometrial carcinoma among the groups (Table 1).29,34 There were no clinically important changes from baseline in number or size of ovarian cysts among the groups. No significant difference was reported in incidence of breast cancer among the groups. There was a significantly lower incidence of fibrocystic breast disease for bazedoxifene compared with raloxifene. Mammogram analyses after 24 months of therapy revealed that the mean percent changes in breast density from baseline were low and did not differ significantly among the groups.35 In the 2-year extension study, bazedoxifene showed no evidence of endometrial or breast stimulation over 5 years of therapy, consistent with findings at 3 years. Fewer cases of endometrial carcinoma were reported in the bazedoxifene group compared with the placebo group.36

**Bazedoxifene-conjugated estrogen combination therapy**

To achieve an ideal balance of estrogen receptor agonist and antagonist activities for optimal menopausal therapy, a novel approach of partnering a SERM with estrogens, designated the tissue-selective estrogen complex, has recently been investigated. Preclinical studies revealed that bazedoxifene antagonized estrogen-induced uterine and mammary gland stimulation more effectively than other SERMs, ie, raloxifene and lasofoxifene.37,38 A randomized, double-blind, placebo-controlled Phase III trial in postmenopausal women (n = 3397) examined the effect of bazedoxifene 10, 20, or 40 mg combined with conjugated estrogens 0.625 mg or 0.45 mg on bone and endometrium as the primary endpoint.39–43 In this trial, the bazedoxifene-conjugated estrogen combination therapy group showed a statistically significant increase in bone mineral density and a decrease in bone turnover markers compared with those on placebo.42 In addition to the favorable effects on bone, bazedoxifene-conjugated estrogen therapy significantly reduced the frequency and severity of hot flushes and improved vulvar-vaginal atrophy and its symptoms compared with placebo, with a good tolerability profile.39–41

**Place of bazedoxifene in management of postmenopausal osteoporosis**

To date, several different types of drugs have been approved for the treatment of osteoporosis. Among them, bisphosphonates are generally considered as first-line therapy for most patients with osteoporosis. Many studies have shown that bisphosphonates increase the bone mineral density and reduce the incidence of fractures in patients with osteoporosis.44–46 However, upper gastrointestinal tract adverse effects, such as nausea, dyspepsia, abdominal pain, and esophagitis, are common with the use of oral bisphosphonates, resulting in discontinuation of treatment.46–48 In addition, long-term bisphosphonate therapy is associated with osteonecrosis of the jaw, defined as exposed nonviable jaw bone, and resistant to treatment.46–50
Hormone replacement therapy was widely recommended for treatment of osteoporosis, as well as for relief of menopausal symptoms. However, a large clinical trial revealed that long-term use of hormone replacement therapy increased the risks of breast cancer and stroke. Consequently, hormone replacement therapy is not usually recommended as a first-line therapy for long-term prevention of osteoporosis in women.

Teriparatide, as a recombinant human parathyroid hormone (PTH1-34), is an anabolic agent that stimulates bone formation and has the potential to improve skeletal microarchitecture. It has been demonstrated that teriparatide increases bone mineral density and significantly reduces fracture risk. However, the use of teriparatide is limited to patients with severe osteoporosis, because it is administered by daily subcutaneous injection and is much more expensive than other drugs used for osteoporosis.

Raloxifene is the first SERM approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene has been shown to increase bone mineral density and reduce the risk of vertebral fracture. In addition to its favorable effects on bone, raloxifene reduces the risk of invasive breast cancer and decreases low-density lipoprotein cholesterol levels. The adverse effects of raloxifene treatment are an increased risk of venous thromboembolism and an increased incidence of vasomotor symptoms. Owing to the limited clinical data for fracture compared with those of bisphosphonates and the potential for serious adverse events, raloxifene is generally considered as a second-line therapy for women with postmenopausal osteoporosis.

Bazedoxifene also showed an increase in bone mineral density and a reduction of risk of vertebral fractures in osteoporotic patients, without stimulating the endometrium or breast. The incidence of nonvertebral fractures in women at a higher fracture risk was also reduced by bazedoxifene compared with placebo or raloxifene. Bazedoxifene was shown to inhibit conjugated estrogen-induced responses in the uterine and mammary glands in animal models more effectively than other SERMs. Taking advantage of the favorable effects of bazedoxifene on the breast and endometrium, the tissue-selective estrogen complex that pairs bazedoxifene with conjugated estrogens is currently under clinical evaluation for the treatment of osteoporosis and menopausal symptoms.

Conclusion
Two global Phase III trials have shown the effectiveness of bazedoxifene in the prevention and treatment of postmenopausal osteoporosis without stimulating the endometrium and breast. Although bazedoxifene is a promising new therapy for patients with osteoporosis, further clinical investigations of long-term treatment with this SERM are needed to evaluate the prevention of osteoporotic fractures, breast cancers, endometrial cancers, and cardiovascular events. When treating patients with osteoporosis, estrogens and SERMs have effects not only on bone metabolism, but also on the breast, endometrium, and lipid metabolism. Before starting treatment, a risk–benefit assessment should be performed for each patient with osteoporosis.

Disclosure
The authors report no conflicts of interest in this work.

References


